Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

NCT05127954 · clinicaltrials.gov ↗
PHASE3
Phase
ENROLLING_BY_INVITATION
Status
1200
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

AbbVie